Skip to main content
Psychopharmacology Bulletin › All Volumes & Issues › VOL 41 No. 1
PSYCHOPHARMACOLOGY BULLETIN

VOL 41 No. 1

Articles in This Issue

ORIGINAL RESEARCH

A Placebo-Controlled Trial of Guanfacine for the Treatment of Post Traumatic Stress Disorder in Veterans

Lori Davis, MD, L. Charles Ward, PhD, Ann Rasmusson, MD, Jason M. Newell, LCSW, PIP, Elizabeth Frazier, MS, and Steven M. Southwick, MD
Preclinical and clinical studies demonstrate a hyperactivity of the norepinephrine system in patients with posttraumatic stress disorder (PTSD). α-2 adrenergic agonists have been shown to ameliorate symptoms of PTSD, likely because of their ability to...
Pages 8-18 Read Article
ORIGINAL RESEARCH

Treatment of Children with Attention-Deficit/Hyperactivity Disorder: Results of a Randomized, Multicenter, Double-Blind, Crossover Study of Extended-Release Dexmethylphenidate and D,L-Methylphenidate and Placebo in a Laboratory Classroom Setting

Raul Silva, MD, Rafael Muniz, MD, Kevin McCague, MA, Ann Childress, MD, Matthew Brams, MD, and Alice Mao, MD
The purpose of this study was to compare the efficacy and safety of extended-release dexmethylphenidate (D-MPH-ER) to that of D,L-MPH-ER and placebo in children with attention-deficit/hyperactivity disorder (ADHD) in a laboratory classroom setting. This multicenter,...
Pages 19-33 Read Article
ORIGINAL RESEARCH

Efficacy of Duloxetine for the Treatment of Depression: Relationship to Most Recent Antidepressant Trial

Timothy Petersen, PhD, Roy H. Perlis, MD, Chris Ticknor, MD, Jim Lohr, MD, H. Brent Solvason, MD, PhD, John P. O’Reardon, MD, Madelaine M. Wohlreich, MD, Charissa Andreotti, BSc, Michael Wilson, MS, and Maurizio Fava, MD
To describe and examine, in a sample of depressed outpatients, the relationship between level of response to a previous SSRI or SNRI antidepressant trial and subsequent response to duloxetine hydrochloride. Experimental Design: Data collected from...
Pages 34-36 Read Article
ORIGINAL RESEARCH

A Pilot Controlled Trial of Bupropion XL Versus Escitalopram in Generalized Anxiety Disorder

By Alexander Bystritsky, MD, Lauren Kerwin, BA, Jamie D. Feusner, MD, and Tanya Vapnik, PhD
Objective: To compare the efficacy and safety of bupropion XL (150–300 mg/day) with the selective serotonin reuptake inhibitor escitalopram (10–20 mg/day) in outpatients diagnosed with generalized anxiety disorder (GAD). Methods: Twenty-four participants with GAD between...
Pages 46-51 Read Article
ORIGINAL RESEARCH

Switching from Other Agents to Extended-Release Carbamazepine in Acute Mania

Alexander Bystritsky, MD, Lauren Kerwin, BA, Jamie D. Feusner, MD, and Tanya Vapnik, PhD
To compare the efficacy and safety of bupropion XL (150–300 mg/day) with the selective serotonin reuptake inhibitor escitalopram (10–20 mg/day) in outpatients diagnosed with generalized anxiety disorder (GAD). Methods: Twenty-four participants with GAD between 18...
Pages 52-58 Read Article
EVIDENCE-BASED MEDICINE

Psychopharmacotherapy in Eating Disorders: A Systematic Analysis

A. Riedl, J. Becker, M. Rauchfuss, and B.F. Klapp
The most common and serious eating disorders, which are particularly prevalent in young women, are anorexia nervosa (AN), bulimia nervosa (BN), and binge-eating disorders (BED). Further, the prevalence of unspecific hyperphagous eating disorders frequently causing...
Pages 59-60 Read Article
EVIDENCE-BASED MEDICINE

Clinical and Pharmacoeconomic Evaluation of Switch to Olanzapine in Veterans with Schizophrenia or Schizoaffective Disorder

Lori L. Davis, MD, Marshall E. Cates, PharmD, BCPP, FASHP, Joette S. Lowe, PharmD, L. Charles Ward, PhD, Jeffrey D. Johnson, RN, BSN, Raela B. Williford, PharmD, Sandra M. Ambrose, MSN, Brandi L. Thomas, LCSW, and Terrell Michael Kashner, PhD, JD, MPH
Background: Second-generation “atypical” antipsychotics improve the outcome of patients with schizophrenia, although studies of their cost efficacy in comparison to first-generation “conventional” antipsychotics have yielded mixed results. Objectives: This study examines the cost effectiveness outcome...
Pages 85-86 Read Article
BRAIN IMAGING

The Revised Dopamine Hypothesis of Schizophrenia: Evidence from Pharmacological MRI Studies with Atypical Antipsychotic Medication

Fabiana da Silva Alves, MS, Martijn Figee, MD, Therese van Amelsvoort, MD, PhD, Dick Veltman, MD, PhD, and Lieuwe de Haan, MD, PhD
The revised dopamine (DA) hypothesis states that clinical symptoms of schizophrenia are caused by an imbalance of the DA system. In this article, we aim to review evidence for this hypothesis by evaluating functional magnetic...
Pages 121-132 Read Article
ORIGINAL RESEARCH

Efficacy of Print Advertising for a Bipolar Disorder Study

Timothy Petersen, PhD, Roy H. Perlis, MD, Chris Ticknor, MD, Jim Lohr, MD, H. Brent Solvason, MD, PhD, John P. O’Reardon, MD, Madelaine M. Wohlreich, MD, Charissa Andreotti, BSc, Michael Wilson, MS, and Maurizio Fava, MD
To describe and examine, in a sample of depressed outpatients, the relationship between level of response to a previous SSRI or SNRI antidepressant trial and subsequent response to duloxetine hydrochloride. Experimental Design: Data collected from...
Pages 136-141 Read Article
COMPLICATED CASE HISTORIES

Drug Dependence Involving Prednisone:Two Cases and a Review of the Literature

Theodore J. Anfinson, MD, Chaitra Channappa, MBBS, and Huyen-Trang Ngoc Vo, BS
Dependence is an unusual, but potentially serious complication of corticosteroid use. Two cases of prednisone dependence are reviewed; the first involving a patient with inflammatory orbital pseudotumor who developed a dependent pattern of prednisone use...
Pages 154-163 Read Article
COMPLICATED CASE HISTORIES

A Potentially Aborted Neuroleptic Malignant Syndrome Following Seclusion Against Uncontrollable Water Intoxication

Takefumi Suzuki, MD, PhD, Hiroyuki Uchida, MD, PhD, Koichiro Watanabe, MD, PhD, and Haruo Kashima, MD, PhD
Water intoxication in schizophrenia poses a great clinical challenge, and infrequently, behavioral restrictions are unavoidable. A patient with refractory schizophrenia comorbid with severe water intoxication had an apparent weight variation of 7 kg/day to 64...
Pages 164-170 Read Article
COMPLICATED CASE HISTORIES

Photophobia and Methylphenidate

Ahmad Ghanizadeh, MD
It is a report of the case of a 7-year-old boy with attention-deficit hyperactive disorder (ADHD), who developed bilateral photophobia when taking methylphenidate (MPH). MPH was stopped and reintroduced many times, and on all of...
Pages 171-173 Read Article